# A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

> **NCT05037097** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 72 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection
- Corona Virus Infection

## Interventions

- **BIOLOGICAL:** ARCT-165
- **BIOLOGICAL:** ARCT-154
- **BIOLOGICAL:** ARCT-021

## Key facts

- **NCT ID:** NCT05037097
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-30
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05037097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05037097, "A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05037097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*